Cargando…
Does the oncology community have a rejection bias when it comes to repurposed drugs?
Among the various measures proposed to combat the challenge of financial toxicity in cancer care, an important strategy is the use of lower-priced drugs instead of expensive alternatives. However, the oncology community seems to either ignore or more readily reject cheaper drugs in cancer care compa...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cancer Intelligence
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813914/ https://www.ncbi.nlm.nih.gov/pubmed/29456622 http://dx.doi.org/10.3332/ecancer.2018.ed76 |